CALL US NOW 0207 939 0780
PLEASE DONATE

Tagged as: hepatitis C

Direct-acting Antiviral (DAA) treatment for Hepatitis C risks Hepatitis B reactivation

New guidance from the Medicines and Healthcare products Regulatory Agency (MHRA) advises that all hepatitis C patients should be screened for hepatitis B before starting treatment with new Direct-acting Antivirals (DAAs). If patients are infected with both viruses this does not preclude treatment but this should be monitored and managed.

Read More